J
Jiansong Huang
Researcher at Zhejiang University
Publications - 52
Citations - 675
Jiansong Huang is an academic researcher from Zhejiang University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 10, co-authored 32 publications receiving 403 citations. Previous affiliations of Jiansong Huang include University of Science and Technology of China & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting
Jiansong Huang,Xia Li,Shi Xiaofeng,Mark Zhu,Jinghan Wang,Shujuan Huang,Xin Huang,Huafeng Wang,Ling Li,Huan Deng,Yulan Zhou,Jian-Hua Mao,Zhangbiao Long,Zhixin Ma,Wenle Ye,Jiajia Pan,Xiaodong Xi,Jie Jin +17 more
TL;DR: The bidirectional signal transduction of integrin αIIbβ3 in platelets is described, as well as the proteins responsible for its regulation and therapeutic agents that target integrinαIIb β3 and its signaling pathways.
Journal ArticleDOI
Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells
Yan-Guang Wang,Ying Zhu,Fuming Qiu,T. Zhang,Zhigang Chen,S. Zheng,Jiansong Huang,Jiansong Huang +7 more
TL;DR: The results revealed the Akt and MAPK pathways were involved in the tumorigenesis of CD133(+) colon cancer cells, suggesting that molecules in these two pathways might be potential targets in the future therapy.
Journal ArticleDOI
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
Jie Jin,Jiang Dz,Wenyuan Mai,Haitao Meng,Wenbin Qian,Hongyan Tong,Jiansong Huang,Liping Mao,Yin Tong,Lei Wang,Zhimei Chen,Weilai Xu +11 more
TL;DR: HAA regimen might be a well-tolerable, effective induction regimen in young adult patients with AML and the toxicities associated with HAA regimen were acceptable, and the most common toxicity was infection.
Journal ArticleDOI
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Xia Li,Chenying Li,Jingrui Jin,Jinghan Wang,Jiansong Huang,Zhixin Ma,Xin Huang,Xiao He,Yile Zhou,Yu Xu,Mengxia Yu,Shujuan Huang,Xiao Yan,Fenglin Li,Jiajia Pan,Yungui Wang,Yongping Yu,Jie Jin +17 more
TL;DR: The synergistic effects of PARP inhibitor BMN673 in combination with SAHA-bendamustine hybrid, NL101, provide a new therapeutic strategy against AML and predicts poor survival in CN-AML patients.
Journal ArticleDOI
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts
Jinghan Wang,Fenglin Li,Zhixin Ma,Mengxia Yu,Qi Guo,Jiansong Huang,Wenjuan Yu,Yungui Wang,Jie Jin +8 more
TL;DR: The TET1 gene expression might serve as a reliable predictor for patients survival in AML, as mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR